Celgene Spreads its Bets in Immuno-Oncology via New Deal with Agios
By Natasha Berry & Heather Cartwright
Pharma Deals Review: Vol 2016 Issue 6 (Table of Contents)
Published: 3 Jun-2016
DOI: 10.3833/pdr.v2016.i6.2162 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Celgene has paid existing partner Agios Pharmaceuticals US$200 M upfront in return for opt-in rights to co-develop and co-commercialise therapies based on Agios’ cellular metabolism research platform...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS